BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.

Andere Sprachen BrightGene Bio-Medical Technology Co., Ltd.

Aktien

688166

CNE100003PR1

688166

Schlusskurs Shanghai S.E. Andere Börsenplätze 00:00:00 06.06.2024			% 5 Tage	% 1. Jan.
34,63 ^CNY	-2,34 %		-4,42 %	-1,06 %

07.05.	Chinesische Aktien steigen dank Erleichterung am Immobilienmarkt; BrightGene springt um 7%	MT
27.04.	BrightGene Bio-Medical Technology Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7%	07.05.
BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3%	07.05.
BrightGene Bio-Medical Technology Co., Ltd. announced that it expects to receive CNY 499.999987 million in funding	06.05.
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	27.04.
Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	02.04.
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25.02.
BrightGene Bio-Medical Technology Co., Ltd. announces an Equity Buyback for CNY 20 million worth of its shares.	07.02.
BrightGene Bio-Medical Technology Co., Ltd. authorizes a Buyback Plan.	06.02.
Oralead Pharma announced that it has received funding from HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd.	29.01.
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26.10.23
Chinese Regulator Issues Warning Against BrightGene Bio-Medical Chairman Over Weight Loss Claims	19.10.23
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs	17.10.23
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	18.08.23
BrightGene Bio-Medical Technology's Unit Gets Hospital's Approval for Diabetes Drug Trial	27.07.23
Chinese Drug Regulator Certifies Two Drugs of BrightGene's Unit	06.07.23
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24.04.23
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27.02.23
BrightGene Bio-Medical to Hike Investment in API Production Project to 500 Million Yuan	08.02.23
Xinchuang Biomedical Technology Subsidiary Gets Nod to Hold Anti-Diabetes Drug Trial	30.12.22
BrightGene Bio-Medical Technology Co., Ltd. announced that it has received CNY 226.613082 million in funding from Horizon Asset Management Co. Ltd., Shanghai Leitu Asset Management Co., Ltd. and other investors	21.11.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BrightGene Bio-Medical Technology Co., Ltd.

Aktien

688166

CNE100003PR1

688166

Andere Sprachen

Filter